文献速递免疫规划传染病防控与疫情报告

新型双价口服脊髓灰质炎疫苗在健康婴儿中的安全性、免疫原性与批间一致性:III期观察者盲法随机对照研究

Safety, immunogenicity and lot-to-lot consistency of a new Bivalent Oral Polio Vaccine (bOPV) in healthy Infants: Results of a Phase III, observer blind, randomized, controlled clinical study.
PubMed 文献 · Vaccine · 2019-06-22

该III期观察者盲法随机对照研究将新型BBio bOPV与已上市SII bOPV进行比较,先在40名5-6岁儿童中评估单剂接种,后在1080名6-8周龄婴儿中按1:1:1:1比例评估3批BBio bOPV或SII bOPV在6、10、14周龄接种的免疫原性与安全性。结果显示所有儿童接种后对1型和3型脊髓灰质炎病毒均达到血清保护,超过96%婴儿出现血清阳转和血清保护,各組GMT可比,3批BBio bOPV的GMT相似,共387名参与者报告至少1例不良事件和18例严重不良事件,均与疫苗无关。结论为新型bOPV免疫原性非劣于已上市bOPV,且3批连续生产批次免疫应答一致,未引起任何不良事件。

要点

  • 所有5-6岁儿童接种单剂后对1型和3型脊髓灰质炎病毒均达血清保护。
  • 超过96%的6-8周龄婴儿接种后对1型和3型病毒出现血清阳转和血清保护。
  • 3批BBio bOPV产生的1型和3型抗体GMT相似,批间一致性得到证明。

核心结论

  • 新型bOPV疫苗免疫原性非劣于已上市bOPV疫苗,3批连续生产批次免疫应答一致,且未引起任何不良事件。

研究设计与样本

  • 观察者盲法、随机、对照III期临床研究,第一部分40名5-6岁儿童按1:1比例单剂接种BBio bOPV或SII bOPV,第二部分1080名6-8周龄婴儿按1:1:1:1比例在6、10、14周龄接种3批BBio bOPV之一或SII bOPV。

主要发现

  • 所有儿童接种后对1型和3型脊髓灰质炎病毒均达到血清保护。
  • 超过96%的婴儿对1型和3型脊髓灰质炎病毒出现血清阳转和血清保护。
  • 各组1型和3型抗体GMT可比,3批BBio bOPV产生的1型和3型抗体GMT相似。
  • 共387名参与者报告至少1例不良事件,18例严重不良事件,均与疫苗无关。

关键数值与推荐

  • 所有5-6岁儿童接种单剂后对1型和3型脊髓灰质炎病毒均血清保护。
  • 超过96%的6-8周龄婴儿对1型和3型脊髓灰质炎病毒血清阳转并血清保护。
  • 3批BBio bOPV产生的1型和3型抗体GMT相似。
  • 387名参与者报告至少1例不良事件,18例严重不良事件,均与疫苗无关。

临床怎么用

  • 该新型bOPV可作为已上市bOPV的替代选择用于婴儿脊髓灰质炎免疫规划,其免疫原性非劣且批间一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poliomyelitis infection continues to be endemic in few countries despite rigorous efforts for eradication. A new Bivalent Oral Polio Vaccine (BBio bOPV) was tested in a Phase III Clinical study. METHODS: An observer blind, randomized, controlled clinical study was conducted comparing BBio bOPV with a licensed bOPV (SII bOPV). Initially in Part 1, 40 children 5-6 years of age were given a single dose of either vaccine in 1:1 ratio. In Part 2, 1080 infants of 6-8 weeks of age were received in 1:1:1:1 ratio one of the 3 lots of BBio bOPV or SII bOPV at 6, 10 and 14 weeks of age. Blood samples were collected to assess neutralizing antibody responses against Polio Type 1 and 3 viruses. Safety of the vaccines were recorded. RESULTS: All children were seroprotected against both Type 1 and Type 3 polioviruses post-vaccination. More than 96% of the infants demonstrated seroconversion as well as seroprotection against both types of polioviruses. The geometric mean titres (GMT) for Type 1 and Type 3 antibodies were comparable between the groups. The 3 lots of BBio bOPV generated similar GMTs of Type 1 and Type 3 antibodies. In total 387 participants reported at least one adverse event and 18 serious adverse events. None of these events were vaccine related. CONCLUSIONS: The new bOPV vaccine demonstrated immunogenicity that was non-inferior to a licensed bOPV vaccine. Consistency in immune response by 3 consecutively manufactured lots was also demonstrated. The vaccine did not cause any adverse event. Clinicaltrials.gov.identifier: NCT02766816.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zaman K, Kingma R, Yunus M, et al. Safety, immunogenicity and lot-to-lot consistency of a new Bivalent Oral Polio Vaccine (bOPV) in healthy Infants: Results of a Phase III, observer blind, randomized, controlled clinical study. Vaccine. 2019. PMID: 31235374. doi:10.1016/j.vaccine.2019.06.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。